HEAL Study
Phase 2, Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System (STS) As An Aid For Smoking Cessation
Short Description
The objectives of this study are to determine the efficacy and safety of selegiline transdermal system (STS) and brief behavioral intervention for smoking cessation in heavy smokers.
Release Date
May 07, 2018

Determine the efficacy of STS with brief behavioral therapy (the investigational intervention) for smoking cessation in heavy smokers. It is hypothesized that the quit rate at the end of treatment for subjects who receive STS with behavioral intervention will be greater than the quit rate for subjects in the placebo patch control group with behavioral intervention.  Determine the safety of the investigational intervention for smoking cessation in heavy smokers as assessed by adverse events, weight gain/loss, vital signs, ECG, and clinical laboratory assessments.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents
Case Report Form(s)
Deidentification Notes